JPMorgan Chase & Co. Raises Holdings in Prestige Consumer Healthcare Inc. $PBH

JPMorgan Chase & Co. increased its stake in shares of Prestige Consumer Healthcare Inc. (NYSE:PBH) by 30.1% in the 3rd quarter, HoldingsChannel reports. The firm owned 459,228 shares of the company’s stock after buying an additional 106,224 shares during the quarter. JPMorgan Chase & Co.’s holdings in Prestige Consumer Healthcare were worth $28,656,000 at the end of the most recent reporting period.

Other large investors have also recently bought and sold shares of the company. First Horizon Corp purchased a new position in Prestige Consumer Healthcare during the third quarter worth $32,000. Barrow Hanley Mewhinney & Strauss LLC lifted its position in shares of Prestige Consumer Healthcare by 106.8% in the third quarter. Barrow Hanley Mewhinney & Strauss LLC now owns 548 shares of the company’s stock valued at $34,000 after acquiring an additional 283 shares in the last quarter. Danske Bank A S purchased a new stake in shares of Prestige Consumer Healthcare in the third quarter valued at $37,000. Hantz Financial Services Inc. boosted its stake in shares of Prestige Consumer Healthcare by 373.6% during the third quarter. Hantz Financial Services Inc. now owns 682 shares of the company’s stock valued at $43,000 after acquiring an additional 538 shares during the last quarter. Finally, Brown Brothers Harriman & Co. acquired a new stake in shares of Prestige Consumer Healthcare during the third quarter valued at $44,000. Institutional investors and hedge funds own 99.95% of the company’s stock.

Analyst Upgrades and Downgrades

Several brokerages recently weighed in on PBH. Jefferies Financial Group cut their target price on shares of Prestige Consumer Healthcare from $70.00 to $66.00 and set a “hold” rating for the company in a research note on Friday, January 30th. Weiss Ratings reaffirmed a “hold (c)” rating on shares of Prestige Consumer Healthcare in a research note on Thursday, January 22nd. Three investment analysts have rated the stock with a Buy rating and four have given a Hold rating to the stock. According to MarketBeat.com, the stock presently has an average rating of “Hold” and a consensus price target of $76.50.

Insider Transactions at Prestige Consumer Healthcare

In other Prestige Consumer Healthcare news, VP Jeffrey Zerillo sold 1,000 shares of the firm’s stock in a transaction dated Wednesday, February 11th. The stock was sold at an average price of $65.93, for a total value of $65,930.00. Following the sale, the vice president directly owned 41,048 shares of the company’s stock, valued at approximately $2,706,294.64. This trade represents a 2.38% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Insiders own 1.40% of the company’s stock.

Prestige Consumer Healthcare Trading Up 2.9%

Shares of PBH opened at $62.77 on Tuesday. Prestige Consumer Healthcare Inc. has a fifty-two week low of $57.25 and a fifty-two week high of $89.37. The company has a market capitalization of $2.97 billion, a PE ratio of 16.61, a price-to-earnings-growth ratio of 1.92 and a beta of 0.41. The stock has a fifty day moving average of $65.77 and a two-hundred day moving average of $63.24. The company has a debt-to-equity ratio of 0.58, a quick ratio of 1.93 and a current ratio of 3.11.

Prestige Consumer Healthcare (NYSE:PBH) last posted its quarterly earnings data on Thursday, February 5th. The company reported $1.14 earnings per share (EPS) for the quarter, missing the consensus estimate of $1.16 by ($0.02). The business had revenue of $283.44 million for the quarter, compared to analyst estimates of $286.93 million. Prestige Consumer Healthcare had a return on equity of 12.02% and a net margin of 16.90%.Prestige Consumer Healthcare’s revenue for the quarter was down 2.4% compared to the same quarter last year. During the same quarter last year, the business earned $1.22 EPS. Prestige Consumer Healthcare has set its FY 2026 guidance at 4.540-4.540 EPS. As a group, analysts forecast that Prestige Consumer Healthcare Inc. will post 4.5 EPS for the current year.

About Prestige Consumer Healthcare

Prestige Consumer Healthcare, Inc is a leading manufacturer and marketer of branded over-the-counter (OTC) healthcare products. The company focuses on developing, acquiring and commercializing a diverse portfolio of non-prescription remedies designed to address common consumer health needs, including pain relief, cold and cough, digestive health, eye care, skin care and women’s health.

Key brands in Prestige’s portfolio include Clear Eyes (eye health), Carmex (lip care), Chloraseptic (sore throat relief), Dramamine (motion sickness), Rolaids (antacid), Monistat (women’s health), BC Powder (pain relief), Little Remedies (pediatric cold and gas relief) and TheraTears (dry eye therapy).